Pfizer and Allergan terminated their previously announced ~$160B merger by mutual agreement following U.S. Treasury anti-inversion regulations issued April 4, 2016, which the companies determined qualified as an Adverse Tax Law Change. Pfizer paid Allergan $150M for expense reimbursement. Originally announced November 2015 with $363.63/share consideration; would have been the largest pharma deal in history.
Key facts
AnnouncedApr 06, 2016
Deal value$160.0B
Deal typeAcquisition/Merger
Therapeutic areaMultiple (medical aesthetics, eye care, CNS, GI)
IndicationsMultiple (medical aesthetics, eye care, CNS, GI)